Revisiting clinical trials on glycemic control and cardiovascular risk
<p>Abstract</p> <p>The most relevant clinical trials, assessing the role of glycemic control in reducing cardiovascular risk, are examined. The UKPDS was the first to address this issue. More recent trials (ACCORD, ADVANCE and VADT) are controversial and evidences did not support t...
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2009-09-01
|
| Series: | Diabetology & Metabolic Syndrome |
| Online Access: | http://www.dmsjournal.com/content/1/1/12 |
| _version_ | 1818346864682991616 |
|---|---|
| author | Ferreira Sandra |
| author_facet | Ferreira Sandra |
| author_sort | Ferreira Sandra |
| collection | DOAJ |
| description | <p>Abstract</p> <p>The most relevant clinical trials, assessing the role of glycemic control in reducing cardiovascular risk, are examined. The UKPDS was the first to address this issue. More recent trials (ACCORD, ADVANCE and VADT) are controversial and evidences did not support that strict glycemic control (reflected by normal glycated hemoglobin) exclusively is sufficient to reduce cardiovascular risk in complicated individuals with long-term type 2 diabetes mellitus. Some possible reasons for controversies are included.</p> |
| first_indexed | 2024-12-13T17:25:03Z |
| format | Article |
| id | doaj.art-d844cd9dac924e0b92f490ffddf6d1a1 |
| institution | Directory Open Access Journal |
| issn | 1758-5996 |
| language | English |
| last_indexed | 2024-12-13T17:25:03Z |
| publishDate | 2009-09-01 |
| publisher | BMC |
| record_format | Article |
| series | Diabetology & Metabolic Syndrome |
| spelling | doaj.art-d844cd9dac924e0b92f490ffddf6d1a12022-12-21T23:37:13ZengBMCDiabetology & Metabolic Syndrome1758-59962009-09-01111210.1186/1758-5996-1-12Revisiting clinical trials on glycemic control and cardiovascular riskFerreira Sandra<p>Abstract</p> <p>The most relevant clinical trials, assessing the role of glycemic control in reducing cardiovascular risk, are examined. The UKPDS was the first to address this issue. More recent trials (ACCORD, ADVANCE and VADT) are controversial and evidences did not support that strict glycemic control (reflected by normal glycated hemoglobin) exclusively is sufficient to reduce cardiovascular risk in complicated individuals with long-term type 2 diabetes mellitus. Some possible reasons for controversies are included.</p>http://www.dmsjournal.com/content/1/1/12 |
| spellingShingle | Ferreira Sandra Revisiting clinical trials on glycemic control and cardiovascular risk Diabetology & Metabolic Syndrome |
| title | Revisiting clinical trials on glycemic control and cardiovascular risk |
| title_full | Revisiting clinical trials on glycemic control and cardiovascular risk |
| title_fullStr | Revisiting clinical trials on glycemic control and cardiovascular risk |
| title_full_unstemmed | Revisiting clinical trials on glycemic control and cardiovascular risk |
| title_short | Revisiting clinical trials on glycemic control and cardiovascular risk |
| title_sort | revisiting clinical trials on glycemic control and cardiovascular risk |
| url | http://www.dmsjournal.com/content/1/1/12 |
| work_keys_str_mv | AT ferreirasandra revisitingclinicaltrialsonglycemiccontrolandcardiovascularrisk |